Location: Boston MA, Providence RI, Westerly RI, Waterford CT,
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sex: All
Age: 18+
Code: NCT04031677
Phase3, Recruiting
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
for
Metastatic Dedifferentiated Liposarcoma,
Location: Boston MA, Baltimore MD, Bethesda MD,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05711615
Phase1, Recruiting
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
for
Leiomyosarcoma, Sarcoma
Location: Columbus OH
Sponsor: Gabriel Tinoco
Sex: All
Age: 18+
Code: NCT06528769
Phase2, Recruiting
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
for
Platinum-Resistant Fallopian Tube Carcinoma,
Location: Scottsdale AZ
Sponsor: Mayo Clinic
Sex: Female
Age: 18+
Code: NCT06483048
Phase1, Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
for
Refractory Diffuse Large B Cell Lymphoma (DLBCL),
Location: Boston MA, New Haven CT, New York NY, Baltimore MD,
Sponsor: Miltenyi Biomedicine GmbH
Sex: All
Age: 18+
Code: NCT04792489
Phase2, Recruiting
Featured
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Location: Providence RI, Teaneck NJ, Fairfax VA, Cincinnati OH,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07024784
Phase2, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
for
Advanced High-Grade Epithelial Ovarian Cancer,
Location: Worcester MA, Pittsburgh PA, Sarasota FL, Detroit MI,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06682988
Phase2, Recruiting
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy